Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer

AI Briefing

• – Theolytics announces first patient dosed in Phase 1 trial for ovarian cancer treatment
• – THEO-260, a novel oncolytic immunotherapy, targets Platinum-Resistant Ovarian Cancer
• – US-based Phase 1 trial evaluates intraperitoneal administration of THEO-260